Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026
Comparison of patient-reported outcomes in patients achieving complete versus near-complete skin clearance following Vunakizumab treatment: a post-hoc analysis of a phase III trial.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04839016 (A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis
Who cites it
1 citing paper in PubMed.
- Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.Biologics : targets & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis post-hoc analysis used the data from a previous randomized controlled trial (NCT04839016) and aimed to compare patient-reported outcomes (PROs) between patients who achieved complete (PASI 100; N = 178) and near-complete (PASI 90-99; N = 181) skin clearance during 12 weeks of Vunakizumab treatment.
methodsPROs included the Dermatology Life Quality Index (DLQI) score, DLQI 0/1 response rate, Itch Numerical Rating Scale (NRS) score, and Short Form-36 (SF-36) Mental Component Score (MCS) and Physical Component Score (PCS).
resultsThe proportion of patients who achieved a DLQI of 0/1 at week (W)8 (P < 0.010), W12 (P < 0.010), W20 (P < 0.001), W28 (P < 0.050), W36 (P < 0.010), and W52 (P < 0.050) was higher in the PASI 100 group compared to the PASI 90-99 group. The mean DLQI score at W4 (P < 0.010), W8 (P < 0.010), W12 (P < 0.001), W20 (P < 0.001), W28 (P < 0.001), W36 (P < 0.001), W44 (P < 0.001), and W52 (P < 0.001), as well as itch NRS score at W8 (P < 0.001), W12 (P < 0.010), W20 (P < 0.001), W28 (P < 0.010), W36 (P < 0.001), W44 (P < 0.010), and W52 (P < 0.010) were lower in the PASI 100 group than in the PASI 90-99 group. The mean SF-36 MCS at W4 (P < 0.050), W12 (P < 0.001), W20 (P < 0.010), W28 (P < 0.001), W36 (P < 0.050), W44 (P < 0.010), and W52 (P < 0.050), as well as SF-36 PCS at W8 (P < 0.050) and W36 (P < 0.050) were higher in the PASI 100 group than in the PASI 90-99 group.
conclusionPatients with complete skin clearance following Vunakizumab treatment showed improved quality of life, reduced pruritus, and enhanced mental health compared to those with near-complete skin clearance.
Indexed as
Identifiers
40853464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.